Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Dosage effect of sorafenib in advanced hepatocellular carcinoma treatment

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: HU, Chun-Liang (Tainan Municipal Hospital, pharmacy)
  • Co-author(s): Chun-Liang Hu: Department of pharmacy, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
    Yang-Cheng Lee: Division of Hemato-Oncology, Department of Internal Medicine, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
    Sheng-Kai Lin: Division of Community Service, Tainan Municipal Hospital (Managed by SHOW CHWAN Medical Care Corporation), Tainan, Taiwan, Province of China
  • Abstract:

    Background

    Sorafenib, an oral multiple tyrosine kinase inhibitor, is the first-line therapy for advanced hepatocellular carcinoma (HCC). When standard dosage (800mg/day) provided, many patients required drug discontinuation or dose reduction due to adverse events (AEs). Some studies reported that starting with a lower sorafenib dose might lead to..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses